CompBrief BY VELARION

Companies Guardant Health, Inc.

Guardant Health (GH): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Guardant Health, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.
CEO total pay$8,661,227CEO AmirAli Talasaz · source
Say-on-pay support90.84%Latest vote · source
CEO vs. named peers12th pct.Of 17 peer CEOs
CEO pay ratio44:1To the median employee · source

CEO pay, last three years

  • $26,415FY2023
  • $11,613,545FY2024
  • $8,661,227FY2025

CEO total pay was $8,661,227 in fiscal 2025, down from $11,613,545 in fiscal 2024.

FY2025: salary $1 · bonus $0 · stock awards $8,647,709 · option awards $0

Executives and directors

AmirAli Talasaz · CEODarya Chudova · CTOJohn Saia · General CounselMichael Bell · CFOCraig Eagle · Chief Medical OfficerHelmy Eltoukhy · CEOAlex M. Azar II · Independent DirectorIan Clark · Lead Independent DirectorManuel Hidalgo Medina · Independent DirectorMeghan Joyce · Independent DirectorMusa Tariq · Independent DirectorMyrtle Potter · Independent DirectorRoberto Mignone · Independent DirectorSteve Krognes · Independent DirectorVijaya Gadde · Independent Director

Frequently asked questions

Who was the highest-paid executive at Guardant Health, Inc. in fiscal 2025?
As disclosed, AmirAli Talasaz (Co-Chief Executive Officer) was the highest-paid executive at Guardant Health, Inc. in fiscal 2025, with total compensation of $8,661,227.
How does Guardant Health, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, AmirAli Talasaz's total compensation ranked at the 12th percentile of Guardant Health, Inc.'s disclosed peer group.
What is Guardant Health, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Guardant Health, Inc.'s CEO-to-median employee pay ratio was 44:1.
How did shareholders vote on Guardant Health, Inc.'s executive compensation?
As disclosed, 90.84% of shareholders supported Guardant Health, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Guardant Health, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Guardant Health, Inc. reported total board compensation of $2,107,851 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
AmirAli Talasaz$1$0$8,647,709$0$0$0$13,517$8,661,227
Co-Chief Executive Officer
Helmy Eltoukhy108,647,70900013,4228,661,132
Chairman and Co-Chief Executive Officer
Michael Bell566,15401,873,317907,059399,000010,8753,756,405
Chief Financial Officer
Darya Chudova520,19210,0001,756,012824,606367,500010,7293,489,039
Chief Technology Officer
John Saia527,1165,0001,545,291725,663371,000011,3143,185,384
Chief Legal Officer and Corporate Secretary
Craig Eagle576,15410,0001,404,827659,701304,500014,9752,970,157
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
AmirAli Talasaz$8,661,227$11,613,545$26,415↓ −2,952,318
Helmy Eltoukhy8,661,13211,613,45011,591↓ −2,952,318
Michael Bell3,756,4053,606,8714,123,993↑ +149,534
Darya Chudova3,489,0393,475,5234,755,541↑ +13,516
John Saia3,185,3843,203,1462,980,104↓ −17,762
Craig Eagle2,970,1573,111,4073,485,356↓ −141,250

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Compensation Committee believes that a well-designed compensation program should align executive interests with the drivers of growth and stockholder returns, incent and reward the Company’s achievement of its strategic business goals, and support the Company’s ability to attract top talent and retain critical employees with the mindset, skills and capabilities to drive and sustain long-term stockholder value.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Helmy EltoukhyRSU2025-03-12——19,258—$830,020
John SaiaRSU2025-03-12——17,866—770,025
Darya ChudovaRSU2025-03-12——20,302—875,016
Michael BellRSU2025-03-12——22,332—962,509
Helmy EltoukhyPSU2025-03-1214,50138,670—96,6751,987,638
Helmy EltoukhyRSU2025-03-12——116,010—5,000,031
John SaiaPSU2025-03-125,65615,083—37,708775,266
John SaiaOPTION2025-03-12——26,799—725,663
Craig EagleOPTION2025-03-12——24,363—659,701
Darya ChudovaOPTION2025-03-12——30,453—824,606
Craig EaglePSU2025-03-125,14213,712—34,280704,797
AmirAli TalasazPSU2025-03-1248119,258—38,516830,020
Darya ChudovaPSU2025-03-126,42817,140—42,850880,996
Helmy EltoukhyPSU2025-03-1248119,258—38,516830,020
AmirAli TalasazRSU2025-03-12——19,258—830,020
Craig EagleRSU2025-03-12——16,242—700,030
AmirAli TalasazPSU2025-03-1214,50138,670—96,6751,987,638
AmirAli TalasazRSU2025-03-12——116,010—5,000,031
Michael BellPSU2025-03-126,64517,720—44,300910,808
Michael BellOPTION2025-03-12——33,498—907,059

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Helmy Eltoukhy$5,830,051$2,817,658$032.6%
John Saia770,025775,266725,66334.1%
Darya Chudova875,016880,996824,60634.1%
Michael Bell962,509910,808907,05932.8%
Craig Eagle700,030704,797659,70134.1%
AmirAli Talasaz5,830,0512,817,658032.6%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Michael BellRSU1,233—$125,939
Michael BellOption1,64530.63—
John SaiaRSU2,039—208,263
Craig EagleRSU2,804—286,401
John SaiaOption3,05932.86—
John SaiaRSU3,896—397,937
Michael BellRSU4,078—416,527
Craig EagleOption4,20632.86—
John SaiaOption5,04754.5—
Darya ChudovaRSU5,357—547,164
Michael BellOption6,11732.86—
John SaiaOption6,49447.2—
Darya ChudovaRSU6,669—681,172
Craig EagleRSU6,669—681,172
John SaiaRSU6,669—681,172
Craig EagleRSU6,857—700,374
John SaiaRSU7,569—773,098
Michael BellRSU8,337—851,541
Darya ChudovaOption8,33728.37—
Craig EagleOption8,33728.37—
John SaiaOption8,33728.37—
Darya ChudovaPSU8,532—871,458
Craig EaglePSU8,532—871,458
John SaiaPSU8,532—871,458
Darya ChudovaOption8,92947.2—
Michael BellOption10,42128.37—
Michael BellPSU10,665—1,089,323
Darya ChudovaPSU11,376—1,161,945
Craig EaglePSU11,376—1,161,945
John SaiaPSU11,376—1,161,945
Craig EagleOption11,42847.2—
Michael BellPSU14,220—1,452,431
John SaiaPSU15,584—1,591,750
Craig EagleRSU16,242—1,658,958
Darya ChudovaRSU17,411—1,778,360
John SaiaRSU17,866—1,824,833
Darya ChudovaOption18,50037.5—
Darya ChudovaRSU20,302—2,073,646
Michael BellPSU21,038—2,148,821
Craig EagleRSU21,274—2,172,926
Darya ChudovaPSU21,428—2,188,656
Michael BellRSU22,332—2,280,990
John SaiaRSU23,401—2,390,178
Craig EagleOption24,36343.1—
John SaiaOption24,82482.83—
Michael BellOption26,467148.19—
Michael BellRSU26,592—2,716,107
Darya ChudovaRSU26,592—2,716,107
John SaiaOption26,79943.1—
Helmy EltoukhyPSU26,961—2,753,817
AmirAli TalasazPSU26,961—2,753,817
Craig EaglePSU27,424—2,801,087
Craig EaglePSU27,426—2,801,292
Craig EagleOption29,25128.61—
John SaiaPSU30,166—3,081,155
Darya ChudovaOption30,45343.1—
John SaiaOption32,17628.61—
Michael BellOption33,49843.1—
Darya ChudovaPSU34,280—3,501,359
Michael BellPSU35,440—3,619,842
Michael BellOption36,56428.61—
Darya ChudovaOption36,56428.61—
Helmy EltoukhyPSU77,340—7,899,508
AmirAli TalasazPSU77,340—7,899,508
Helmy EltoukhyRSU116,010—11,849,261
AmirAli TalasazRSU116,010—11,849,261
Helmy EltoukhyRSU119,986—12,255,370
AmirAli TalasazRSU119,986—12,255,370
Helmy EltoukhyPSU286,533—29,266,481
AmirAli TalasazPSU286,533—29,266,481
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Alex M. Azar IIIndependent · Governance$0$362,527$362,805$0$0$725,332
Ian ClarkIndependent · Lead Independent Director · Governance (Chair)0257,502212,74000470,242
Vijaya GaddeIndependent · Compensation (Chair)0212,546212,74000425,286
Roberto MignoneIndependent · Audit0212,546212,74000425,286
Manuel Hidalgo MedinaIndependent · Governance0212,546212,74000425,286
Meghan JoyceIndependent · Audit · Compensation · Not standing for re-election0212,546212,74000425,286
Myrtle PotterIndependent · Audit · Compensation0212,546212,74000425,286
Musa TariqIndependent · Governance0212,546212,74000425,286
Steve KrognesIndependent · Audit (Chair)0212,546212,74000425,286

Board fee structure and ownership guideline

Annual cash retainer$60,000
Annual equity retainer$350,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000 / 15,000
Stock ownership guideline$250,000

Total cost of the board

ComponentFY2025
Cash retainers and fees$0
Equity awards (grant-date value)$2,107,851
All other compensation$0
Total cost of the board$2,107,851

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Guardant Health as a peer

Companies that benchmark against GH

18 companies name GH as a compensation peer

Each company listed discloses GH in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GH in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

NBIX Neurocrine Biosciences, Inc.IRTC iRhythm Technologies, Inc.TEM Tempus AI, Inc.MIRM BioMarin Pharmaceuticals Inc.NTRA Natera, Inc.UTHR United Therapeutics CorpACAD ACADIA Pharmaceuticals Inc.PODD Insulet CorporationALNY Alnylam Pharmaceuticals, Inc.MASI Masimo CorporationCAI Caris Life Sciences, Inc.DXCM Dexcom, Inc.NEO NeoGenomics, Inc.EXAS Exact Sciences CorporationEXEL Exelixis, Inc.IDXX IDEXX Laboratories, Inc.ILMN Illumina, Inc.

Peer reciprocity

Of the companies Guardant Health, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

— Neurocrine Biosciences, Inc. (NBIX)261— iRhythm Technologies, Inc. (IRTC)262✓ Tempus AI, Inc. (TEM)263— BioMarin Pharmaceuticals Inc. (MIRM)264✓ Natera, Inc. (NTRA)265— United Therapeutics Corp (UTHR)266— ACADIA Pharmaceuticals Inc. (ACAD)267— Insulet Corporation (PODD)268— Alnylam Pharmaceuticals, Inc. (ALNY)269— Masimo Corporation (MASI)270 Caris Life Sciences, Inc. (CAI)— Dexcom, Inc. (DXCM)271✓ NeoGenomics, Inc. (NEO)272✓ Exact Sciences Corporation (EXAS)273— Exelixis, Inc. (EXEL)274— IDEXX Laboratories, Inc. (IDXX)275— Illumina, Inc. (ILMN)276

Reciprocity shown where the peer’s own current proxy has been read — each mark is cited in the register to that peer’s filing. A dash means the peer’s current proxy was read and names no reciprocal group including Guardant Health, Inc..

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Tempus AI, Inc.2025Eric Lefkofsky$783,333$39,992,500$0$720,000$41,495,833
2Exelixis, Inc.2025Michael Morrissey1,306,04030,539,55201,382,59133,239,183
3Caris Life Sciences, Inc.2025David Dean Halbert764,91815,400,5690020,350,571
4Masimo Corporation2025Catherine Szyman850,04816,388,6931,399,9981,130,00019,797,140
5Insulet Corporation2025Ashley McEvoy729,80812,958,8502,999,9132,031,56218,858,968
6United Therapeutics Corp2025Martine Rothblatt1,545,0056,067,9906,075,8044,281,87518,038,972
7Exact Sciences Corporation2024Kevin Conroy1,083,36813,496,1380712,32915,539,378
8Natera, Inc.2025Steven Chapman853,71012,979,55801,114,15114,957,319
9Alnylam Pharmaceuticals, Inc.2025Yvonne Greenstreet1,404,2005,512,5004,363,3803,562,50014,867,600
10Idexx Laboratories, Inc.2025Jonathan Mazelsky1,150,0005,399,8815,400,0012,593,00014,580,122
11Neurocrine Biosciences, Inc.2025Kyle Gano920,0005,750,0235,750,006013,448,935
12Illumina, Inc.2025Jacob Thaysen1,000,0008,763,12201,155,00011,018,895
13iRhythm Technologies, Inc.2025Quentin Blackford700,0038,919,45701,350,00011,003,163
14BioMarin Pharmaceuticals Inc.2025Christopher Peetz755,0003,683,9044,931,3201,057,00010,441,224
15NeoGenomics, Inc.2025Tony Zook601,5393,999,9973,998,235513,4009,127,092
16Guardant Health, Inc.2025AmirAli Talasaz18,647,709008,661,227
17Acadia Pharmaceuticals Inc.2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
18Dexcom, Inc.2025Jacob Leach768,9625,936,06201,164,7807,985,960

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Guardant Health, Inc.140%PSU 50 · RSU 50 · Option 35NoAon
Acadia Pharmaceuticals Inc.110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Alnylam Pharmaceuticals, Inc.200%PSU 50 · RSU 25 · Option 25NoPay Governance
BioMarin Pharmaceuticals Inc.200%Option 47.2 · PSU 17.6 · RSU 17.6NoAlpine Rewards
Caris Life Sciences, Inc.115%RSU 100not disclosedCompensia, Inc.
Dexcom, Inc.not disclosednot disclosedYes — Relative TSR Performance MetricAon Hewitt Consulting Company
Exact Sciences Corporation47%PSU 60 · RSU 40NoAon
Exelixis, Inc.105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Idexx Laboratories, Inc.140%Options 50 · PSU 50NoFarient
Illumina, Inc.not disclosednot disclosedYes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology IndexAon
Insulet Corporation195.8%PSU 60 · RSU 20 · Options 20NoPearl Meyer & Partners, LLC
iRhythm Technologies, Inc.173%RSU 50 · PSU 50Yes — Relative TSRAon and Mercer
Masimo Corporationnot disclosednot disclosednot disclosedFW Cook
Natera, Inc.131.1%PSU 50 · RSU 50NoAon
NeoGenomics, Inc.60%RSU 50 · Options 50not disclosedWTW
Neurocrine Biosciences, Inc.105%Option 50 · PRSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
Tempus AI, Inc.90%PSU 100Yes — TSR of at least 300 basis points higher than the return of the Nasdaq Composite IndexCompensia, Inc.
United Therapeutics Corp221%PSO 50 · PSU 50NoAon

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1798,236,6399,905,190301,61090.84%Passed
20252025-06-1891,189,7027,020,245364,53492.85%Passed
20242024-06-1284,585,9465,812,828604,76693.57%Passed
20232023-06-1466,909,18510,481,515178,80686.46%Passed
20222022-06-1550,606,02332,094,830427,61061.19%Passed
20212021-06-1631,453,28251,134,93174,07138.08%Failed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20262026-06-1790.84%a
20252025-06-1892.85%b
20242024-06-1293.57%c

a. Approved under the standard stated in the filing — “Abstentions are considered to be votes not cast on this proposal and thus will have no effect.”.

b. Approved under the standard stated in the filing — “Abstentions are considered to be votes not cast on this proposal and thus will have no effect.”.

c. Approved under the standard stated in the filing — “Abstentions are considered to be votes not cast on this proposal and thus will have no effect.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)44 : 1
CEO total compensation$8,661,227
Median employee compensation$198,418
Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Michael BellChief Financial Officer2026-07-01A2,084$0$0CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01A1,99400CommonForm 4 ↗
AmirAli TalasazDirector2026-07-01D23,99700Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-07-01D9,71500Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-07-01A9,71500CommonForm 4 ↗
Dividend-equivalent accruals2026-07-01—23,009——6 insiders, 15 accrual rows
Michael BellChief Financial Officer2026-07-01D3,32400Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-07-01D2,08400Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-07-01D3,914171668,394CommonForm 4 ↗
Michael BellChief Financial Officer2026-07-01A1,87000CommonForm 4 ↗
Michael BellChief Financial Officer2026-07-01A3,32400CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01D3,32400Derivative, Class A CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01A1,70000CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01A3,32400CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01A1,66700CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01A1,33900CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01D2,52600Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01D3,141171536,389CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01A1,29300CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01A2,52600CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01A1,66700CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01A1,92800CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01D3,066171523,581CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01A1,36100CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01A1,08400CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01A1,60700CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-07-01D2,65900Derivative, Class A CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-07-01A2,65900CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01D2,92500Derivative, Class A CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01D3,707171633,044CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01A1,66700CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01A97400CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01D4,318171737,385CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-07-01A1,36100CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01A2,92500CommonForm 4 ↗
AmirAli TalasazDirector2026-07-01D9,71500Derivative, Class A CommonForm 4 ↗
AmirAli TalasazDirector2026-07-01D17,0861712,917,776CommonForm 4 ↗
AmirAli TalasazDirector2026-07-01A9,71500CommonForm 4 ↗
AmirAli TalasazDirector2026-07-01A23,99700CommonForm 4 ↗
Helmy EltoukhyDirector2026-07-01D23,99700Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-07-01D17,0861712,917,776CommonForm 4 ↗
Helmy EltoukhyDirector2026-07-01A23,99700CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-07-01D2,099171358,446CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01A1,49700CommonForm 4 ↗
Dividend-equivalent accruals2026-07-15—250——1 insider, 1 accrual row
Musa TariqDirector2026-07-15A25000CommonForm 4 ↗
Musa TariqDirector2026-07-16D11616318,942CommonForm 4 ↗
Dividend-equivalent accruals2026-07-17—232——1 insider, 1 accrual row
Medina Manuel HidalgoDirector2026-07-17A23200CommonForm 4 ↗
Dividend-equivalent accruals2026-07-21—264——1 insider, 1 accrual row
Roberto MignoneDirector2026-07-21A26400CommonForm 4 ↗
Ian ClarkDirector2026-08-04D5,092159808,626CommonForm 4 ↗
Ian ClarkDirector2026-08-04D9,0881591,444,825CommonForm 4 ↗
Ian ClarkDirector2026-08-04A6,83351345,545CommonForm 4 ↗
Ian ClarkDirector2026-08-04A2,25591205,453CommonForm 4 ↗
Ian ClarkDirector2026-08-04D6,83300Derivative, Class A CommonForm 4 ↗
Ian ClarkDirector2026-08-04D2,25500Derivative, Class A CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-08-05D750165123,454CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-08-05A9503330,923CommonForm 4 ↗
Dividend-equivalent accruals2026-08-05—950——1 insider, 1 accrual row
Medina Manuel HidalgoDirector2026-08-05D950164155,748CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D28,19300Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D3,463167579,639CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10A28,19328799,835CommonForm 4 ↗
John SaiaChief Legal Officer2026-08-10D80000CommonForm 4 ↗
AmirAli TalasazDirector2026-08-10A75,00000CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10A35,4121103,912,672CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D35,41200Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D17,4131702,964,401CommonForm 4 ↗
AmirAli TalasazDirector2026-08-10D75,00000CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D35,3641705,998,926CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D7,3651691,243,145CommonForm 4 ↗
Helmy EltoukhyDirector2026-08-11A35,00000CommonForm 4 ↗
Helmy EltoukhyDirector2026-08-11D35,00000CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D14,01200Derivative, Class A CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D13,2481662,200,584CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D19,0141653,140,310CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D9,9341641,631,870CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D3,704163605,286CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12A14,01229400,883CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12A32,28820650,280CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D32,28800Derivative, Class A CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D40016867,168CommonForm 4 ↗
Musa TariqDirector2026-08-15A25000CommonForm 4 ↗
Dividend-equivalent accruals2026-08-15—250——1 insider, 1 accrual row
Musa TariqDirector2026-08-17D11615618,148CommonForm 4 ↗
Dividend-equivalent accruals2026-08-17—232——1 insider, 1 accrual row
Medina Manuel HidalgoDirector2026-08-17A23200CommonForm 4 ↗
Dividend-equivalent accruals2026-08-21—264——1 insider, 1 accrual row
Roberto MignoneDirector2026-08-21A26400CommonForm 4 ↗
AmirAli TalasazDirector2026-08-21D7,5891701,292,302CommonForm 4 ↗
AmirAli TalasazDirector2026-08-21D20,8881693,533,452CommonForm 4 ↗
AmirAli TalasazDirector2026-08-21D9,0231681,517,631CommonForm 4 ↗
Helmy EltoukhyDirector2026-08-26A25,00000CommonForm 4 ↗
Helmy EltoukhyDirector2026-08-26D25,00000CommonForm 4 ↗
Helmy EltoukhyDirector2026-08-26D30,00000CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-09-11D4,000158632,193CommonForm 4 ↗
Dividend-equivalent accruals2026-09-12—1,651——1 insider, 1 accrual row
Alex M. Azar IIDirector2026-09-12A1,65100CommonForm 4 ↗
Musa TariqDirector2026-09-15A24900CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-09-15D7,7381781,377,364CommonForm 4 ↗
Dividend-equivalent accruals2026-09-15—249——1 insider, 1 accrual row
Steve KrognesDirector2026-09-16D971177172,330CommonForm 4 ↗
Steve KrognesDirector2026-09-16D1,300176229,236CommonForm 4 ↗
Alex M. Azar IIDirector2026-09-16D826175144,550CommonForm 4 ↗
Musa TariqDirector2026-09-16D11617520,300CommonForm 4 ↗
Steve KrognesDirector2026-09-16D3,300175578,888CommonForm 4 ↗
Steve KrognesDirector2026-09-16D1,103174192,432CommonForm 4 ↗
Dividend-equivalent accruals2026-09-17—232——1 insider, 1 accrual row
Medina Manuel HidalgoDirector2026-09-17A23200CommonForm 4 ↗
Dividend-equivalent accruals2026-09-21—264——1 insider, 1 accrual row
Roberto MignoneDirector2026-09-21A26400CommonForm 4 ↗
AmirAli TalasazDirector2026-09-30D2,81700Derivative, Class A CommonForm 4 ↗
AmirAli TalasazDirector2026-09-30D1,428178254,698CommonForm 4 ↗
AmirAli TalasazDirector2026-09-30A2,81700CommonForm 4 ↗
Helmy EltoukhyDirector2026-09-30D2,81700Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-09-30D1,428178254,698CommonForm 4 ↗
Helmy EltoukhyDirector2026-09-30A2,81700CommonForm 4 ↗
Dividend-equivalent accruals2026-10-01—23,013——6 insiders, 15 accrual rows
Darya ChudovaChief Technology Officer2026-10-01D3,32400Derivative, Class A CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01D4,320175754,920CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01A1,70100CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01A3,32400CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01A1,66800CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01D2,92500Derivative, Class A CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01D3,706175647,624CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01A1,34000CommonForm 4 ↗
AmirAli TalasazDirector2026-10-01D9,71600Derivative, Class A CommonForm 4 ↗
AmirAli TalasazDirector2026-10-01D23,99700Derivative, Class A CommonForm 4 ↗
AmirAli TalasazDirector2026-10-01D17,0871752,985,953CommonForm 4 ↗
AmirAli TalasazDirector2026-10-01A9,71600CommonForm 4 ↗
AmirAli TalasazDirector2026-10-01A23,99700CommonForm 4 ↗
Helmy EltoukhyDirector2026-10-01D9,71600Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-10-01D23,99700Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-10-01D17,0871752,985,953CommonForm 4 ↗
Helmy EltoukhyDirector2026-10-01A9,71600CommonForm 4 ↗
Helmy EltoukhyDirector2026-10-01A23,99700CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-10-01D2,65900Derivative, Class A CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-10-01D2,098175366,626CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01A1,49600CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01A2,92500CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01A1,66800CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01A97400CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-10-01A1,36000CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-10-01A2,65900CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01D3,067175535,958CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01A1,36000CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01A1,99500CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01A1,08400CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01A1,60700CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01D2,52700Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01D3,143175549,239CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01A1,29200CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01A2,52700CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01A1,66800CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01A1,92900CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01D3,32400Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01D2,08500Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01D3,914175683,972CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01A1,87100CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01A3,32400CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01A2,08500CommonForm 4 ↗
Dividend-equivalent accruals2026-10-12—137——1 insider, 1 accrual row
Alex M. Azar IIDirector2026-10-12A13700CommonForm 4 ↗
Alex M. Azar IIDirector2026-10-14D6916011,032CommonForm 4 ↗
Musa TariqDirector2026-10-15A25000CommonForm 4 ↗
Dividend-equivalent accruals2026-10-15—250——1 insider, 1 accrual row
Musa TariqDirector2026-10-16D11616619,242CommonForm 4 ↗
Dividend-equivalent accruals2026-10-17—232——1 insider, 1 accrual row
Medina Manuel HidalgoDirector2026-10-17A23200CommonForm 4 ↗
Dividend-equivalent accruals2026-10-21—264——1 insider, 1 accrual row
Roberto MignoneDirector2026-10-21A26400CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 200 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Michael BellChief Financial Officer2026-07-01A2,084$0$0CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01A1,99400CommonForm 4 ↗
AmirAli TalasazDirector2026-07-01D23,99700Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-07-01D9,71500Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-07-01A9,71500CommonForm 4 ↗
Michael BellChief Financial Officer2026-07-01D1,87000Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-07-01D3,32400Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-07-01D2,08400Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-07-01D3,914171668,394CommonForm 4 ↗
Michael BellChief Financial Officer2026-07-01A1,87000CommonForm 4 ↗
Michael BellChief Financial Officer2026-07-01A3,32400CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01D1,70000Derivative, Class A CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01D3,32400Derivative, Class A CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01D1,66700Derivative, Class A CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01D1,33900Derivative, Class A CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01A1,70000CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01A3,32400CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01A1,66700CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01A1,33900CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01D1,29300Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01D2,52600Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01D1,66700Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01D1,92800Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01D3,141171536,389CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01A1,29300CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01A2,52600CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01A1,66700CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-07-01A1,92800CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01D1,36100Derivative, Class A CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01D1,99400Derivative, Class A CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01D1,08400Derivative, Class A CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01D1,60700Derivative, Class A CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01D3,066171523,581CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01A1,36100CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01A1,08400CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-07-01A1,60700CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-07-01D1,36100Derivative, Class A CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-07-01D2,65900Derivative, Class A CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-07-01A2,65900CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01D2,92500Derivative, Class A CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01D1,66700Derivative, Class A CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01D97400Derivative, Class A CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01D3,707171633,044CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01A1,66700CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01A97400CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-07-01D4,318171737,385CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-07-01A1,36100CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01D1,49700Derivative, Class A CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01A2,92500CommonForm 4 ↗
AmirAli TalasazDirector2026-07-01D9,71500Derivative, Class A CommonForm 4 ↗
AmirAli TalasazDirector2026-07-01D17,0861712,917,776CommonForm 4 ↗
AmirAli TalasazDirector2026-07-01A9,71500CommonForm 4 ↗
AmirAli TalasazDirector2026-07-01A23,99700CommonForm 4 ↗
Helmy EltoukhyDirector2026-07-01D23,99700Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-07-01D17,0861712,917,776CommonForm 4 ↗
Helmy EltoukhyDirector2026-07-01A23,99700CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-07-01D2,099171358,446CommonForm 4 ↗
John SaiaChief Legal Officer2026-07-01A1,49700CommonForm 4 ↗
Musa TariqDirector2026-07-15D25000Derivative, Class A CommonForm 4 ↗
Musa TariqDirector2026-07-15A25000CommonForm 4 ↗
Musa TariqDirector2026-07-16D11616318,942CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-07-17D23200Derivative, Class A CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-07-17A23200CommonForm 4 ↗
Roberto MignoneDirector2026-07-21D26400Derivative, Class A CommonForm 4 ↗
Roberto MignoneDirector2026-07-21A26400CommonForm 4 ↗
Ian ClarkDirector2026-08-04D5,092159808,626CommonForm 4 ↗
Ian ClarkDirector2026-08-04D9,0881591,444,825CommonForm 4 ↗
Ian ClarkDirector2026-08-04A6,83351345,545CommonForm 4 ↗
Ian ClarkDirector2026-08-04A2,25591205,453CommonForm 4 ↗
Ian ClarkDirector2026-08-04D6,83300Derivative, Class A CommonForm 4 ↗
Ian ClarkDirector2026-08-04D2,25500Derivative, Class A CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-08-05D750165123,454CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-08-05A9503330,923CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-08-05D95000Derivative, Class A CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-08-05D950164155,748CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D28,19300Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D3,463167579,639CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10A28,19328799,835CommonForm 4 ↗
John SaiaChief Legal Officer2026-08-10D80000CommonForm 4 ↗
AmirAli TalasazDirector2026-08-10A75,00000CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10A35,4121103,912,672CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D35,41200Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D17,4131702,964,401CommonForm 4 ↗
AmirAli TalasazDirector2026-08-10D75,00000CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D35,3641705,998,926CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-08-10D7,3651691,243,145CommonForm 4 ↗
Helmy EltoukhyDirector2026-08-11A35,00000CommonForm 4 ↗
Helmy EltoukhyDirector2026-08-11D35,00000CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D14,01200Derivative, Class A CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D13,2481662,200,584CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D19,0141653,140,310CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D9,9341641,631,870CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D3,704163605,286CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12A14,01229400,883CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12A32,28820650,280CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D32,28800Derivative, Class A CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-08-12D40016867,168CommonForm 4 ↗
Musa TariqDirector2026-08-15A25000CommonForm 4 ↗
Musa TariqDirector2026-08-15D25000Derivative, Class A CommonForm 4 ↗
Musa TariqDirector2026-08-17D11615618,148CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-08-17D23200Derivative, Class A CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-08-17A23200CommonForm 4 ↗
Roberto MignoneDirector2026-08-21D26400Derivative, Class A CommonForm 4 ↗
Roberto MignoneDirector2026-08-21A26400CommonForm 4 ↗
AmirAli TalasazDirector2026-08-21D7,5891701,292,302CommonForm 4 ↗
AmirAli TalasazDirector2026-08-21D20,8881693,533,452CommonForm 4 ↗
AmirAli TalasazDirector2026-08-21D9,0231681,517,631CommonForm 4 ↗
Helmy EltoukhyDirector2026-08-26A25,00000CommonForm 4 ↗
Helmy EltoukhyDirector2026-08-26D25,00000CommonForm 4 ↗
Helmy EltoukhyDirector2026-08-26D30,00000CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-09-11D4,000158632,193CommonForm 4 ↗
Alex M. Azar IIDirector2026-09-12D1,65100Derivative, Class A CommonForm 4 ↗
Alex M. Azar IIDirector2026-09-12A1,65100CommonForm 4 ↗
Musa TariqDirector2026-09-15A24900CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-09-15D7,7381781,377,364CommonForm 4 ↗
Musa TariqDirector2026-09-15D24900Derivative, Class A CommonForm 4 ↗
Steve KrognesDirector2026-09-16D971177172,330CommonForm 4 ↗
Steve KrognesDirector2026-09-16D1,300176229,236CommonForm 4 ↗
Alex M. Azar IIDirector2026-09-16D826175144,550CommonForm 4 ↗
Musa TariqDirector2026-09-16D11617520,300CommonForm 4 ↗
Steve KrognesDirector2026-09-16D3,300175578,888CommonForm 4 ↗
Steve KrognesDirector2026-09-16D1,103174192,432CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-09-17D23200Derivative, Class A CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-09-17A23200CommonForm 4 ↗
Roberto MignoneDirector2026-09-21D26400Derivative, Class A CommonForm 4 ↗
Roberto MignoneDirector2026-09-21A26400CommonForm 4 ↗
AmirAli TalasazDirector2026-09-30D2,81700Derivative, Class A CommonForm 4 ↗
AmirAli TalasazDirector2026-09-30D1,428178254,698CommonForm 4 ↗
AmirAli TalasazDirector2026-09-30A2,81700CommonForm 4 ↗
Helmy EltoukhyDirector2026-09-30D2,81700Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-09-30D1,428178254,698CommonForm 4 ↗
Helmy EltoukhyDirector2026-09-30A2,81700CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01D1,70100Derivative, Class A CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01D3,32400Derivative, Class A CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01D1,66800Derivative, Class A CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01D1,34000Derivative, Class A CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01D4,320175754,920CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01A1,70100CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01A3,32400CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01A1,66800CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01D2,92500Derivative, Class A CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01D3,706175647,624CommonForm 4 ↗
Darya ChudovaChief Technology Officer2026-10-01A1,34000CommonForm 4 ↗
AmirAli TalasazDirector2026-10-01D9,71600Derivative, Class A CommonForm 4 ↗
AmirAli TalasazDirector2026-10-01D23,99700Derivative, Class A CommonForm 4 ↗
AmirAli TalasazDirector2026-10-01D17,0871752,985,953CommonForm 4 ↗
AmirAli TalasazDirector2026-10-01A9,71600CommonForm 4 ↗
AmirAli TalasazDirector2026-10-01A23,99700CommonForm 4 ↗
Helmy EltoukhyDirector2026-10-01D9,71600Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-10-01D23,99700Derivative, Class A CommonForm 4 ↗
Helmy EltoukhyDirector2026-10-01D17,0871752,985,953CommonForm 4 ↗
Helmy EltoukhyDirector2026-10-01A9,71600CommonForm 4 ↗
Helmy EltoukhyDirector2026-10-01A23,99700CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-10-01D1,36000Derivative, Class A CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-10-01D2,65900Derivative, Class A CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-10-01D2,098175366,626CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01A1,49600CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01A2,92500CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01A1,66800CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01A97400CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-10-01A1,36000CommonForm 4 ↗
Terilyn J. MonroeChief People Officer2026-10-01A2,65900CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01D1,36000Derivative, Class A CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01D1,99500Derivative, Class A CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01D1,08400Derivative, Class A CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01D1,60700Derivative, Class A CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01D3,067175535,958CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01A1,36000CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01A1,99500CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01A1,08400CommonForm 4 ↗
Kumud KaliaChief Information Officer2026-10-01A1,60700CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01D1,29200Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01D2,52700Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01D1,66800Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01D1,92900Derivative, Class A CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01D3,143175549,239CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01A1,29200CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01A2,52700CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01A1,66800CommonForm 4 ↗
Chris FreemanChief Commercial Officer2026-10-01A1,92900CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01D1,49600Derivative, Class A CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01D1,66800Derivative, Class A CommonForm 4 ↗
John SaiaChief Legal Officer2026-10-01D97400Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01D1,87100Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01D3,32400Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01D2,08500Derivative, Class A CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01D3,914175683,972CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01A1,87100CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01A3,32400CommonForm 4 ↗
Michael BellChief Financial Officer2026-10-01A2,08500CommonForm 4 ↗
Alex M. Azar IIDirector2026-10-12D13700Derivative, Class A CommonForm 4 ↗
Alex M. Azar IIDirector2026-10-12A13700CommonForm 4 ↗
Alex M. Azar IIDirector2026-10-14D6916011,032CommonForm 4 ↗
Musa TariqDirector2026-10-15A25000CommonForm 4 ↗
Musa TariqDirector2026-10-15D25000Derivative, Class A CommonForm 4 ↗
Musa TariqDirector2026-10-16D11616619,242CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-10-17D23200Derivative, Class A CommonForm 4 ↗
Medina Manuel HidalgoDirector2026-10-17A23200CommonForm 4 ↗
Roberto MignoneDirector2026-10-21D26400Derivative, Class A CommonForm 4 ↗
Roberto MignoneDirector2026-10-21A26400CommonForm 4 ↗
Sources (276 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, AmirAli Talasaz. DEF 14A, filed 2026-04-28. Section “Compensation Tables” · page 65. As printed: 8,661,227. View filing ↗
  • Section 01, Helmy Eltoukhy. DEF 14A, filed 2026-04-28. Section “Compensation Tables”. As printed: 8,661,132. View filing ↗
  • Section 01, Michael Bell. DEF 14A, filed 2026-04-28. Section “Compensation Tables”. As printed: 3,756,405. View filing ↗
  • Section 01, Darya Chudova. DEF 14A, filed 2026-04-28. Section “Compensation Tables”. As printed: 3,489,039. View filing ↗
  • Section 01, John Saia. DEF 14A, filed 2026-04-28. Section “Compensation Tables”. As printed: 3,185,384. View filing ↗
  • Section 01, Craig Eagle. DEF 14A, filed 2026-04-28. Section “Compensation Tables”. As printed: 2,970,157. View filing ↗
  • Section 03, Helmy Eltoukhy RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, John Saia RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Darya Chudova RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Michael Bell RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Helmy Eltoukhy PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Helmy Eltoukhy RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, John Saia PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, John Saia OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Craig Eagle OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Darya Chudova OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Craig Eagle PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, AmirAli Talasaz PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Darya Chudova PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Helmy Eltoukhy PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, AmirAli Talasaz RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Craig Eagle RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, AmirAli Talasaz PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, AmirAli Talasaz RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Michael Bell PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Michael Bell OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 44 : 1. View filing ↗
  • Section 08, Alex M. Azar II. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 725,332. View filing ↗
  • Section 08, Ian Clark. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 470,242. View filing ↗
  • Section 08, Vijaya Gadde. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 425,286. View filing ↗
  • Section 08, Roberto Mignone. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 425,286. View filing ↗
  • Section 08, Manuel Hidalgo Medina. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 425,286. View filing ↗
  • Section 08, Meghan Joyce. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 425,286. View filing ↗
  • Section 08, Myrtle Potter. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 425,286. View filing ↗
  • Section 08, Musa Tariq. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 425,286. View filing ↗
  • Section 08, Steve Krognes. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 425,286. View filing ↗
  • Section 02, Michael Bell 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-07-15. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-07-16. Form 4, filed 2026-07-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-07-17. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-07-17. Form 4, filed 2026-07-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Roberto Mignone 2026-07-21. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Roberto Mignone 2026-07-21. Form 4, filed 2026-07-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ian Clark 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ian Clark 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ian Clark 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ian Clark 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ian Clark 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ian Clark 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-08-05. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-08-05. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-08-05. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-08-05. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-08-10. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-08-10. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-08-10. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-08-10. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-08-10. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-08-10. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-08-10. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-08-10. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Roberto Mignone 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Roberto Mignone 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-08-26. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-08-26. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-08-26. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-09-11. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alex M. Azar II 2026-09-12. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alex M. Azar II 2026-09-12. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Steve Krognes 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Steve Krognes 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alex M. Azar II 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Steve Krognes 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Steve Krognes 2026-09-16. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Roberto Mignone 2026-09-21. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Roberto Mignone 2026-09-21. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Darya Chudova 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, AmirAli Talasaz 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helmy Eltoukhy 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Terilyn J. Monroe 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kumud Kalia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chris Freeman 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John Saia 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Bell 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alex M. Azar II 2026-10-12. Form 4, filed 2026-10-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alex M. Azar II 2026-10-12. Form 4, filed 2026-10-13. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alex M. Azar II 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-10-15. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Musa Tariq 2026-10-16. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-10-17. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Medina Manuel Hidalgo 2026-10-17. Form 4, filed 2026-10-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Roberto Mignone 2026-10-21. Form 4, filed 2026-10-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Roberto Mignone 2026-10-21. Form 4, filed 2026-10-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2026 vote. Form 8-K, filed 2026-06-18. Item 5.07 · say-on-pay result. As reported: 90.84% (votes for as printed: 98,236,639). View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-06-20. Item 5.07 · say-on-pay result. As reported: 92.85% (votes for as printed: 91,189,702). View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 93.57% (votes for as printed: 84,585,946). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 0 + equity 2,107,851 + all other 0 = 2,107,851, summed across the director compensation table rows.
  • Tempus AI, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tempus AI, Inc.'s own proxy. As printed: 41,495,833. View filing ↗
  • Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
  • Caris Life Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Caris Life Sciences, Inc.'s own proxy. As printed: 20,350,571. View filing ↗
  • Masimo Corporation, Section 10b CEO total. 10-K/A, filed 2026-05-01. CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 19,797,140. View filing ↗
  • Insulet Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Insulet Corporation's own proxy. As printed: 18,858,968. View filing ↗
  • United Therapeutics Corp, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corp's own proxy. As printed: 18,038,972. View filing ↗
  • Exact Sciences Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. View filing ↗
  • Natera, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. View filing ↗
  • Alnylam Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. View filing ↗
  • Idexx Laboratories, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Idexx Laboratories, Inc.'s own proxy. As printed: 14,580,122. View filing ↗
  • Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
  • Illumina, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. View filing ↗
  • iRhythm Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in iRhythm Technologies, Inc.'s own proxy. As printed: 11,003,163. View filing ↗
  • BioMarin Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioMarin Pharmaceuticals Inc.'s own proxy. As printed: 10,441,224. View filing ↗
  • NeoGenomics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. View filing ↗
  • Guardant Health, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. View filing ↗
  • Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
  • Dexcom, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Dexcom, Inc.'s own proxy. As printed: 7,985,960. View filing ↗
  • Section 10a, Neurocrine Biosciences, Inc. reciprocity. DEF 14A. Neurocrine Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, iRhythm Technologies, Inc. reciprocity. DEF 14A. iRhythm Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, Tempus AI, Inc. reciprocity. DEF 14A. Tempus AI, Inc. names Guardant Health, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, BioMarin Pharmaceuticals Inc. reciprocity. DEF 14A. BioMarin Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, Natera, Inc. reciprocity. DEF 14A. Natera, Inc. names Guardant Health, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, United Therapeutics Corp reciprocity. DEF 14A. United Therapeutics Corp's most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, ACADIA Pharmaceuticals Inc. reciprocity. DEF 14A. ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, Insulet Corporation reciprocity. DEF 14A. Insulet Corporation's most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity. DEF 14A. Alnylam Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, Masimo Corporation reciprocity. DEF 14A. Masimo Corporation's most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, Dexcom, Inc. reciprocity. DEF 14A. Dexcom, Inc.'s most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, NeoGenomics, Inc. reciprocity. DEF 14A. NeoGenomics, Inc. names Guardant Health, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Exact Sciences Corporation reciprocity. DEF 14A. Exact Sciences Corporation names Guardant Health, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Exelixis, Inc. reciprocity. DEF 14A. Exelixis, Inc.'s most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, IDEXX Laboratories, Inc. reciprocity. DEF 14A. IDEXX Laboratories, Inc.'s most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
  • Section 10a, Illumina, Inc. reciprocity. DEF 14A. Illumina, Inc.'s most recent proxy was read; its disclosed peer group does not include Guardant Health, Inc.. View filing ↗
Get the full report — $500